WO2014193647A3 - Composés alcényles et procédés d'utilisation - Google Patents

Composés alcényles et procédés d'utilisation Download PDF

Info

Publication number
WO2014193647A3
WO2014193647A3 PCT/US2014/037856 US2014037856W WO2014193647A3 WO 2014193647 A3 WO2014193647 A3 WO 2014193647A3 US 2014037856 W US2014037856 W US 2014037856W WO 2014193647 A3 WO2014193647 A3 WO 2014193647A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
alkenyl compounds
compositions
modulating
Prior art date
Application number
PCT/US2014/037856
Other languages
English (en)
Other versions
WO2014193647A2 (fr
Inventor
Ning Xi
Xiaobo Li
Original Assignee
Calitor Sciences, Llc
Sunshine Lake Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calitor Sciences, Llc, Sunshine Lake Pharma Co., Ltd. filed Critical Calitor Sciences, Llc
Publication of WO2014193647A2 publication Critical patent/WO2014193647A2/fr
Publication of WO2014193647A3 publication Critical patent/WO2014193647A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés alcényles substitués, des sels et des formulations pharmaceutiquement acceptables de ceux-ci utiles pour moduler l'activité de la protéine tyrosine kinase, ainsi que pour moduler des activités cellulaires comme la prolifération, la différenciation, l'apoptose, la migration et l'invasion. L'invention concerne en outre des compositions pharmaceutiquement acceptables comprenant de tels composés ainsi que des procédés d'utilisation des compositions dans le traitement de troubles hyperprolifératifs chez des mammifères, notamment les êtres humains.
PCT/US2014/037856 2013-05-26 2014-05-13 Composés alcényles et procédés d'utilisation WO2014193647A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827599P 2013-05-26 2013-05-26
US61/827,599 2013-05-26

Publications (2)

Publication Number Publication Date
WO2014193647A2 WO2014193647A2 (fr) 2014-12-04
WO2014193647A3 true WO2014193647A3 (fr) 2015-01-29

Family

ID=51989510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/037856 WO2014193647A2 (fr) 2013-05-26 2014-05-13 Composés alcényles et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2014193647A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017013310A (es) 2015-04-21 2018-02-26 Jiangsu Hengrui Medicine Co Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico.
CN106188116B (zh) * 2016-07-14 2018-02-06 沧州普瑞东方科技有限公司 一种合成吡唑‑4‑硼酸频那醇酯的方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106831720B (zh) * 2017-01-21 2019-04-16 河北科技大学 双-4-(1h-吡唑-1-基)哌啶-1-甲酸叔丁酯的合成方法及其应用
KR102093540B1 (ko) 2017-08-11 2020-03-25 주식회사 엘지화학 할로겐 치환된 스티렌 모노머의 제조방법
KR102213040B1 (ko) * 2017-12-20 2021-02-05 한국원자력의학원 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도
CN113874015B (zh) 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
CN110698506A (zh) * 2019-11-27 2020-01-17 怀化旺达生物科技有限公司 一种吡唑-4-硼酸频哪醇酯的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004350A1 (en) * 2000-06-19 2003-01-02 Pharmacia & Upjohn Azaindole derivatives, process for their preparation, and their use as antitumor agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004350A1 (en) * 2000-06-19 2003-01-02 Pharmacia & Upjohn Azaindole derivatives, process for their preparation, and their use as antitumor agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUKY, ZT. ET AL.: "Cyclocondensation reaction of heterocyclic carbonyl compounds, Part XIII: Synthesis and cytotoxic activity of some 3,7-diaryl- 5-(3,4,5-timethoxyphenyl)pyrazolo[4,3-e] [1,2,4]triazines.", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 2, 2009, pages 891 - 900, XP025950222, Retrieved from the Internet <URL:http://www.researchgate.net/publication151406782_Cyclocondensation_reaction_of_heterocyclic_carbonyl_compounds._Part_XIII_synthesis_and_cytotoxic_activity_of_some_37-diaryl-5-%28345-trimethoxyphenyl%29pyrazolo43-e124triazines> doi:10.1016/j.ejmech.2008.05.026 *

Also Published As

Publication number Publication date
WO2014193647A2 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2014022116A8 (fr) Composés de pyrazolone substituée et leurs procédés d&#39;utilisation
MX352844B (es) Compuestos de quinolina sustituidos y metodos de uso.
WO2014193647A3 (fr) Composés alcényles et procédés d&#39;utilisation
AU2018236800B2 (en) DNA-PK inhibitors
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CL2016001895A1 (es) Compuestos
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MY182036A (en) Heteroaromatic compounds as pi3 kinase modulators
MY180641A (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
WO2014019908A3 (fr) Pyrroles substitués actifs en tant qu&#39;inhibiteurs de kinase
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201400772A1 (ru) Варианты полипептидов ph20, композиции на их основе и их применение
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
PH12019501079A1 (en) Magl inhibitors
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
EP3539951A4 (fr) Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires
EP3336100A4 (fr) Peptide ayant pour effet de prévenir ou traiter des maladies du système nerveux central et composition pharmaceutique pour la prévention et le traitement de maladies du système nerveux central, contenant ce dernier en tant que principe actif
EP2578590A4 (fr) Composé anti-inflammatoire ayant une activité inhibitrice contre des tyrosine kinases multiples, et composition pharmaceutique contenant celui-ci
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
EP3053601A4 (fr) Composition pharmaceutique pour prévenir et traiter un cancer, contenant le gène ou la protéine cyb5r3 en tant que substance active
EP3551208A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de l&#39;alopécie comprenant un extrait d&#39;eremochloa ophiuroides ou des fractions de celui-ci à titre de principe actif
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14804067

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14804067

Country of ref document: EP

Kind code of ref document: A2